N. Anthony Coles - Feb 6, 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: CEO and Chairperson, Director
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol: CERE
Transactions as of: Feb 6, 2023
Transactions value $: -$1,481,401
Form type: 4
Date filed: 2/8/2023, 07:27 PM
Previous filing: Jan 6, 2023
Next filing: Mar 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$175 K	+50 K	+1849.11%	$3.50	52.7 K	Feb 7, 2023	Direct	F1
transaction	CERE	Common Stock	Sale	-$1.39 M	-42.1 K	-79.8%	$33.04	10.6 K	Feb 7, 2023	Direct	F1, F2
transaction	CERE	Common Stock	Sale	-$267 K	-7.94 K	-74.6%	$33.57	2.7 K	Feb 7, 2023	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Award	$0	+243 K		$0.00	243 K	Feb 6, 2023	Common Stock	243 K	$34.41	Direct	F4
transaction	CERE	Restricted Stock Units	Award	$0	+61.8 K		$0.00	61.8 K	Feb 6, 2023	Common Stock	61.8 K		Direct	F5, F6
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-50 K	-1.67%	$0.00	2.95 M	Feb 7, 2023	Common Stock	50 K	$3.50	Direct	F1, F7

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person.
F2	The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 - $33.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.44 - $34.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F5	The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F6	The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date.
F7	25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter.